>Dr Reddy's- Merck Serono biologic partnership
Catalyst: Biosimilar remains an interesting opportunity
The deal appears well timed, as some clarity on regulatory pathways has begun to emerge in its developed markets of the US and Europe. With biologic drugs of USD100bn+ in sales going off-patent by 2020, we estimate the biosimilar opportunity in developed markets to record ~50% CAGR to reach USD20bn by 2020F. Also, we expect a 3-fold growth in patient volumes in emerging markets by 2020F as affordability increases on lower prices of biosimilars. Dr Reddy's biosimilar revenue of USD25mn (FY12) is <5% of the overall biosimilar market currently, on our reading.
Valuation: Maintain Buy
The deal does not impact our estimates but reduces risk. At 16x FY13F P/E, the valuations appear reasonable. Our TP implies 19% upside.
To read report in detail: DR. REDDY's LABORATORIES
RISH TRADER